Drug Marketing in Focus: Risk Monitoring Now Mandatory for Promotional Activities and More Pharmaceutical Businesses Subject to BPOM Oversight

The National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan – “BPOM”) has issued Regulation No. 7 of 2026 on the Promotion and Advertising of Drugs (“Regulation 7/2026”). This framework has now repealed and replaced Regulation of the BPOM No. 2 of 2021 on Guidelines for Drug Advertising (“Regulation 2/2021”), while retaining existing advertising approvals, meaning that approvals that were secured under Regulation 7/2026 will remain valid. Businesses have been granted a 12-month compliance grace period that will run until 29 April 2027 in order to bring their advertisements and promotional materials into line with the new framework.[1]